No connection

Search Results

ARVN vs OMDA

ARVN
Arvinas, Inc.
BEARISH
Price
$12.18
Market Cap
$782.3M
Sector
Healthcare
AI Confidence
85%
OMDA
Omada Health, Inc.
BEARISH
Price
$13.12
Market Cap
$773.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARVN
--
OMDA
--
Forward P/E
ARVN
-3.49
OMDA
36.59
P/B Ratio
ARVN
1.78
OMDA
3.34
P/S Ratio
ARVN
2.98
OMDA
2.97
EV/EBITDA
ARVN
-0.92
OMDA
-84.98

Profitability

Gross Margin
ARVN
100.0%
OMDA
65.69%
Operating Margin
ARVN
-754.74%
OMDA
4.33%
Profit Margin
ARVN
-30.77%
OMDA
-4.91%
ROE
ARVN
-16.23%
OMDA
-8.68%
ROA
ARVN
-7.94%
OMDA
-3.28%

Growth

Revenue Growth
ARVN
-84.0%
OMDA
58.1%
Earnings Growth
ARVN
--
OMDA
--

Financial Health

Debt/Equity
ARVN
0.02
OMDA
--
Current Ratio
ARVN
4.92
OMDA
3.6
Quick Ratio
ARVN
4.86
OMDA
3.4

Dividends

Dividend Yield
ARVN
--
OMDA
--
Payout Ratio
ARVN
0.0%
OMDA
0.0%

AI Verdict

ARVN BEARISH

ARVN's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score suggests no solvency validation. Despite a strong gross margin of 100.00%, the company reports a -30.77% profit margin, -754.74% operating margin, and an 84% YoY revenue decline, signaling fundamental business deterioration. Insider selling activity totaling $0.83M over six months, with multiple officer and CEO sales, reinforces bearish sentiment. While the stock has rebounded 42.5% over the past year, this is likely driven by speculative momentum rather than fundamentals, and the current price of $12.18 remains elevated relative to its deteriorating performance.

Strengths
Gross margin of 100.00% indicates potential product pricing power or low production costs
Extremely low debt/equity ratio of 0.02 suggests minimal financial leverage risk
High current and quick ratios (4.92 and 4.86) reflect strong short-term liquidity
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
84% YoY revenue decline and negative operating margin (-754.74%) indicate business contraction and unsustainable operations
Insider selling of $0.83M in the last 6 months, including CEO and officer sales, signals loss of confidence
OMDA BEARISH

OMDA exhibits a critical disconnect between high revenue growth and deteriorating financial health, evidenced by a weak Piotroski F-Score of 2/9. While the company shows strong top-line expansion (58.1% YoY) and positive earnings surprises, the technical trend is completely bearish and insider sentiment is heavily negative. The high current ratio provides a liquidity cushion, but the aggressive selling by the CEO and other executives suggests a lack of internal confidence in the current valuation. Despite analyst 'Buy' recommendations and a higher target price, the fundamental health and price action indicate significant risk.

Strengths
Strong revenue growth of 58.10% YoY
High gross margins at 65.69%
Strong short-term liquidity with a current ratio of 3.60
Risks
Very weak Piotroski F-Score (2/9) indicating poor fundamental health
Heavy insider selling, specifically by the CEO and CFO
Severe price depreciation (-48.4% over the last 6 months)

Compare Another Pair

ARVN vs OMDA: Head-to-Head Comparison

This page compares Arvinas, Inc. (ARVN) and Omada Health, Inc. (OMDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile